Today Medasense announced that it has raised $18M in a series C round, from Sabadell Asabys venture capital firm (Asabys Partners, Spain), Israeli family offices and returning investors Baxter Ventures, Olive Tree Ventures and LGL Capital.
Josep Ll. Sanfeliu, founding partner of Asabys Partners stated: “Medasense is a model startup, having successfully introduced a disruptive medical device technology to the market. Its artificial intelligence solution is impacting clinical outcomes to benefit patients and to enable better use of healthcare resources.”
“Together with our trusted investors, who share our passion to improve pain management, we expect to make a significant contribution to enhancing pain care,” said Galit Zuckerman-Stark, Medasense founder and CEO. “This funding round will allow us to expand and further consolidate commercial deployment of NOL technology in Europe through our distribution agreement with Medtronic and to complete the process of obtaining FDA approval for commercialization in the U.S.”
Contact firstname.lastname@example.org for more information.